Phase 3 Readout

MBX: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label

Name: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label
Start: 2029-08-01
End: 2029-08-01

August 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: August 1, 2029
Company: MBX Biosciences, Inc. (MBX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label

August 1, 2029

MBX overview →

Company: MBX Biosciences, Inc. (MBX)
Indication: Hypoparathyroidism